BRPI0515979A - composto, processo para a preparação do mesmo, composições, uso de um ou mais compostos, e, método de tratamento de um paciente sofrendo de um distúrbio - Google Patents
composto, processo para a preparação do mesmo, composições, uso de um ou mais compostos, e, método de tratamento de um paciente sofrendo de um distúrbioInfo
- Publication number
- BRPI0515979A BRPI0515979A BRPI0515979-2A BRPI0515979A BRPI0515979A BR PI0515979 A BRPI0515979 A BR PI0515979A BR PI0515979 A BRPI0515979 A BR PI0515979A BR PI0515979 A BRPI0515979 A BR PI0515979A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compositions
- treating
- compound
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Abstract
"COMPOSTO,PROCESSO PARA A PREPARAçãO DO MESMO,COMPOSIçõES, USO OU MAIS COMPOSTOS, E, MéTODO DE TRATAMENTO DE UM PACIENTE SOFRENDO De UM DISTúRBIO".A invenção refere-se a 1-¢2-(4-benzil-4-hidróxi-piperidin-1-il )-etil-3-!(2-metil-quinolin-4-il)-uréia como um sal de sulfato cristalino,estequiomentricamente defenido e não higroscópico e a um processo para sua preparação. Além disso,a presente invenção refere-se ao uso referida 1-¢2-(4-benzil-4hidróxi-piperidin-1-il)-eti-3-(2-metil-quinolin-4-il)-uréia como um sal de sulfato cristalino,estequiometricamente defenido e não higroscópico,sozinha ou em combinação com outros compostos.Além disso,a presente invenção refere-se às fomulações da referida1-¢2-(4-benzil-4-hidróxi-piperidin-1-il)-eti-!-3-(2-metil-quinolin-4-i l)-uréia,como um sal de sulfato cristalino,esquiometricamente definido e não hidroscópico,na preparação das composições farmacêuticas.A invenção também refere-se ao uso de tais sais de sulfato nas formulações,como antagonistas neuro-hormonais.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP2004011410 | 2004-10-12 | ||
PCT/IB2005/053340 WO2006040728A1 (en) | 2004-10-12 | 2005-10-11 | 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea as crystalline sulfate salt |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0515979A true BRPI0515979A (pt) | 2008-08-12 |
Family
ID=35457837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0515979-2A BRPI0515979A (pt) | 2004-10-12 | 2005-10-11 | composto, processo para a preparação do mesmo, composições, uso de um ou mais compostos, e, método de tratamento de um paciente sofrendo de um distúrbio |
Country Status (12)
Country | Link |
---|---|
US (1) | US8067601B2 (pt) |
JP (1) | JP5139066B2 (pt) |
KR (1) | KR101271372B1 (pt) |
CN (1) | CN101039930B (pt) |
AR (1) | AR051213A1 (pt) |
AU (1) | AU2005293196B2 (pt) |
BR (1) | BRPI0515979A (pt) |
CA (1) | CA2583845C (pt) |
MX (1) | MX2007004293A (pt) |
RU (1) | RU2397978C2 (pt) |
TW (1) | TWI362387B (pt) |
WO (1) | WO2006040728A1 (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3008619B1 (fr) * | 2013-07-16 | 2018-04-20 | Centre Hospitalier Universitaire De Rouen | Antagonistes, agonistes partiels et agonistes inverses du recepteur de l'urotensine ii pour leur utilisation dans la prevention des deficits neurologiques consecutifs a une hemorragie sous-arachnoidienne |
CN110755434B (zh) * | 2018-07-27 | 2022-03-15 | 中国医学科学院药物研究所 | 化合物palosuran防治骨骼肌萎缩等疾病的用途 |
CN116139140A (zh) * | 2021-11-19 | 2023-05-23 | 中国医学科学院药物研究所 | 一种化合物在治疗糖皮质激素不良反应中的用途 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI97540C (fi) | 1989-11-06 | 1997-01-10 | Sanofi Sa | Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi |
US6159700A (en) | 1997-01-27 | 2000-12-12 | Smithkline Beecham Corporation | Method of finding agonist and antagonist to human and rat GPR14 |
AUPP003197A0 (en) | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
US6331541B1 (en) * | 1998-12-18 | 2001-12-18 | Soo S. Ko | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
ATE321751T1 (de) | 1999-07-28 | 2006-04-15 | Kirin Brewery | Harnstoffderivate als ccr-3 rezeptor-inhibitoren |
ATE249831T1 (de) | 1999-12-21 | 2003-10-15 | Smithkline Beecham Corp | Carboxamidderivate von pyrrolidine und piperidine als urotensin-ii rezeptorantagonisten |
ES2225297T3 (es) | 1999-12-21 | 2005-03-16 | Smithkline Beecham Corporation | Antagonistas del receptor de urotensina ii. |
WO2001045694A1 (en) | 1999-12-21 | 2001-06-28 | Smithkline Beecham Corporation | Urotensin-ii receptor antagonists |
EP1262195A4 (en) | 2000-03-07 | 2003-05-21 | Takeda Chemical Industries Ltd | VASOACTIVE AGENTS |
WO2002000606A1 (fr) | 2000-06-28 | 2002-01-03 | Takeda Chemical Industries, Ltd. | Compose biphenyle |
US20040063699A1 (en) | 2000-07-04 | 2004-04-01 | Naoki Tarui | Gpr14 antagonist |
JP2004515530A (ja) | 2000-12-11 | 2004-05-27 | スミスクライン・ビーチャム・コーポレイション | ウロテンシン−ii受容体アンタゴニスト |
JP2004515507A (ja) | 2000-12-11 | 2004-05-27 | スミスクライン・ビーチャム・コーポレイション | ウロテンシン−ii受容体アンタゴニスト |
WO2002058702A1 (en) | 2001-01-26 | 2002-08-01 | Smithkline Beecham Corporation | Urotensin-ii receptor antagonists |
BR0207715A (pt) | 2001-03-27 | 2004-03-23 | Actelion Pharmaceuticals Ltd | Compostos, composições farmacêuticas, e uso de um ou mais compostos |
JP2004524355A (ja) | 2001-03-29 | 2004-08-12 | スミスクライン・ビーチャム・コーポレイション | ピロリジンスルホンアミド |
US20040152692A1 (en) | 2001-03-29 | 2004-08-05 | Dashyant Dhanak | Pyrrolidine sulfonamides |
JP2004525156A (ja) | 2001-03-29 | 2004-08-19 | スミスクライン・ビーチャム・コーポレイション | ピロリジンスルホンアミド |
EP1379237A2 (en) | 2001-03-29 | 2004-01-14 | Smithkline Beecham Corporation | Pyrrolidine sulfonamides |
AR033879A1 (es) | 2001-05-07 | 2004-01-07 | Smithkline Beecham Corp | Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto |
JP2005508852A (ja) | 2001-05-07 | 2005-04-07 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
US6849635B2 (en) | 2001-05-07 | 2005-02-01 | Smithkline Beecham Corporation | Sulfonamides |
WO2002089793A1 (en) | 2001-05-07 | 2002-11-14 | Smithkline Beecham Corporation | Sulfonamides |
WO2002090353A1 (en) | 2001-05-07 | 2002-11-14 | Smithkline Beecham Corporation | Sulfonamides |
WO2002090337A1 (en) | 2001-05-07 | 2002-11-14 | Smithkline Beecham Corporation | Sulfonamides |
ES2254772T3 (es) * | 2001-12-04 | 2006-06-16 | Actelion Pharmaceuticals Ltd. | 4-(piperidil-y pirrolidil-alquil-ureido)-quinoleinas como receptores antagonistas de urotensina ii. |
MXPA05002839A (es) * | 2002-09-17 | 2005-05-27 | Actelion Pharmaceuticals Ltd | Derivados de 1-piridin-4-il-urea. |
AR041885A1 (es) | 2002-11-06 | 2005-06-01 | Smithkline Beecham Corp | Compuesto de sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion |
AU2003291303A1 (en) | 2002-11-06 | 2004-06-03 | Smithkline Beecham Corporation | Sulfonamides |
AU2003291255A1 (en) | 2002-11-06 | 2004-06-03 | Smithkline Beecham Corporation | Sulfonamides |
WO2004043369A2 (en) | 2002-11-06 | 2004-05-27 | Smithkline Beecham Corporation | Sulfonamides |
AU2003295408A1 (en) | 2002-11-06 | 2004-06-03 | Smithkline Beecham Corporation | Sulfonamides |
EP1610753A4 (en) | 2003-02-20 | 2007-07-04 | Encysive Pharmaceuticals Inc | UROTENSIN-II RECEPTOR ANTAGONISTS OF PHENYLENEDIAMINE AND ANTAGONISTS OF CCR-9 |
CN1784395A (zh) | 2003-05-07 | 2006-06-07 | 埃科特莱茵药品有限公司 | 哌嗪-烷基-脲基衍生物 |
CN1856305B (zh) * | 2003-09-26 | 2010-04-28 | 埃科特莱茵药品有限公司 | 用作尾加压素ⅱ拮抗剂的吡啶衍生物 |
-
2005
- 2005-10-11 KR KR1020077010700A patent/KR101271372B1/ko not_active IP Right Cessation
- 2005-10-11 MX MX2007004293A patent/MX2007004293A/es active IP Right Grant
- 2005-10-11 BR BRPI0515979-2A patent/BRPI0515979A/pt not_active IP Right Cessation
- 2005-10-11 JP JP2007535321A patent/JP5139066B2/ja not_active Expired - Fee Related
- 2005-10-11 RU RU2007117502/04A patent/RU2397978C2/ru not_active IP Right Cessation
- 2005-10-11 WO PCT/IB2005/053340 patent/WO2006040728A1/en active Application Filing
- 2005-10-11 AU AU2005293196A patent/AU2005293196B2/en not_active Ceased
- 2005-10-11 CN CN2005800346899A patent/CN101039930B/zh not_active Expired - Fee Related
- 2005-10-11 US US11/577,064 patent/US8067601B2/en not_active Expired - Fee Related
- 2005-10-11 AR ARP050104260A patent/AR051213A1/es not_active Application Discontinuation
- 2005-10-11 CA CA2583845A patent/CA2583845C/en not_active Expired - Fee Related
- 2005-10-12 TW TW094135555A patent/TWI362387B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2005293196B2 (en) | 2012-03-22 |
US8067601B2 (en) | 2011-11-29 |
KR20070063589A (ko) | 2007-06-19 |
AU2005293196A1 (en) | 2006-04-20 |
JP5139066B2 (ja) | 2013-02-06 |
CA2583845C (en) | 2013-03-26 |
CN101039930A (zh) | 2007-09-19 |
TW200626578A (en) | 2006-08-01 |
JP2008515877A (ja) | 2008-05-15 |
US20090023775A1 (en) | 2009-01-22 |
CA2583845A1 (en) | 2006-04-20 |
RU2397978C2 (ru) | 2010-08-27 |
WO2006040728A1 (en) | 2006-04-20 |
CN101039930B (zh) | 2010-08-11 |
RU2007117502A (ru) | 2008-11-20 |
TWI362387B (en) | 2012-04-21 |
KR101271372B1 (ko) | 2013-06-07 |
AR051213A1 (es) | 2006-12-27 |
MX2007004293A (es) | 2007-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0606793A8 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica | |
BRPI0514691A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
BRPI0519181A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, e, mÉtodos para produzir um efeito inibitàrio de b-raf em um animal de sangue quente, para produzir um efeito anti-cÂncer em um animal de sangue quente e para tratar uma doenÇa em um animal de sangue quente | |
BR0108378A (pt) | Sal cristalino de um composto, composição farmacêutica, processo para a manufatura do dito sal, e, uso do mesmo | |
BR0213242A (pt) | Composto ou um seu sal ou solvato, composto e seus sais de adição de ácido fisiologicamente aceitáveis, composição farmacêutica, método de tratamento de um ou mais distúrbios, uso de um composto, e, processo de preparação de um composto | |
TN2012000263A1 (en) | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof. | |
ME00060B (me) | Nova heterociklična jedinjenja, njihovo dobijanje i njihova upotreba kao medikamenata, a naročito kao anti-bakterijskih agenasa | |
BRPI0516454A (pt) | compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii | |
BR0113039A (pt) | Composto ou um seu sal ou solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica em aerossol, método para o tratamento de um indivìduo humano ou animal com uma condição antiinflamatória e/ou alérgica, e, processo para preparar um composto | |
BRPI0509668A (pt) | composto, composição farmacêutica que compreende o mesmo, método de tratamento de enfermidade, distúrbio ou sintoma inflamatório e método de preparação do composto | |
BR0313732A (pt) | Compostos de pirimido tendo atividade antiproliferativa | |
BR0307267A (pt) | Compostos heterocìclicos, ativos como inibidores de beta-lacta-mases | |
BR0113120A (pt) | Composto ou sal, composição farmacêutica, método para alterar a atividade transdutora de sinal de receptores gabaa, método para o tratamento de ansiedade, depressão, um distúrbio do sono, ou demência de alzheimer, método para demonstrar a presença de receptores de gabaa em amostras de célula ou tecido, embalagem, e, uso de um composto ou sal | |
BR0111377A (pt) | Derivados de tiofeno úteis como agentes anticancerìgenos | |
ATE554086T1 (de) | Scopin-salze und deren verwendung in verfahren zur herstellung von n-demethyl-tiotropium und tiotropiumbromid | |
BRPI0519208A2 (pt) | derivados de pirrolinÍdio como receptores muscarÍnicos m3 | |
BRPI0511424A (pt) | composto, composição farmacêutica, uso de um composto, método de tratamento ou profilaxia de doenças inflamatórias, e, processo para a preparação de um composto | |
BRPI0515979A (pt) | composto, processo para a preparação do mesmo, composições, uso de um ou mais compostos, e, método de tratamento de um paciente sofrendo de um distúrbio | |
BR112018077257A2 (pt) | derivados de 5,7-di-hidro-pirrolo-piridina para o tratamento de doenças neurológicas e neurodegenerativas | |
BRPI0414780B8 (pt) | composto, uso do mesmo, composição farmacêutica, e, método para preparar um composto | |
BR0308419A (pt) | Derivados de azetidina como antagonistas do receptor ccr-3 | |
BRPI0517565A (pt) | compostos, uso de um ou mais compostos, composição farmacêutica, e, processo para a fabricação de composições farmacêuticas | |
BR0315995A (pt) | Composto, uso de um composto composição farmacêutica, métodos para a terapia da dor, de distúrbios gastrointestinais, e da ansiedade em um animal de sangue quente, e, processo para preparar um composto | |
BRPI0409302A (pt) | derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos | |
BRPI0809873A2 (pt) | "composto, processo para a preparação do composto, método para o tratamento de uma desordem do sistema nervoso central, composição farmacêutica, uso do composto, método para testar antagonistas e antagonistas com seletividade para o receptor 5-th6 e método de tratamento" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 11A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |